A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
Anita D SouzaNina ShahCesar RodriguezPeter M VoorheesKatja WeiselOrlando F BuenoRajvineeth K PothacamuryKevin J FreiseSusan YueJeremy A RossAkshanth R PolepallyChetasi TalatiShane LeeZiyi JinBen BuelowRavi VijShaji K KumarPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
ABBV-383 in patients with RRMM was well tolerated with an ORR of 68% at doses ≥ 40 mg. This novel therapy's promising preliminary antitumor activity in heavily pretreated patients warrants further clinical evaluation.
Keyphrases
- multiple myeloma
- clinical evaluation
- end stage renal disease
- endothelial cells
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acute lymphoblastic leukemia
- acute myeloid leukemia
- peritoneal dialysis
- prognostic factors
- diffuse large b cell lymphoma
- stem cells
- patient reported outcomes
- mesenchymal stem cells
- induced pluripotent stem cells